Bristol-Myers Squibb
BMY
$65.16
Share price
-0.49%
Change (1 day)
-14.92%
Change (1 year)
Categories
Bristol-Myers Squibb (BMY) - Cash on Hand
Cash on Hand as of March 2023 : $8.99 B
According to Bristol-Myers Squibb's latest financial reports the company has $8.99 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Bristol-Myers Squibb - Cash on Hand chart (from 2001 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2022-12-31 | $9.25 B | -46.27% |
| 2021-12-31 | $17.22 B | 4.69% |
| 2020-12-31 | $16.45 B | 6.87% |
| 2019-12-31 | $15.39 B | 73.27% |
| 2018-12-31 | $8.88 B | 30.42% |
| 2017-12-31 | $6.81 B | 7.28% |
| 2016-12-31 | $6.35 B | 48.71% |
| 2015-12-31 | $4.27 B | -42.57% |
| 2014-12-31 | $7.43 B | 64.31% |
| 2013-12-31 | $4.52 B | 59.95% |
| 2012-12-31 | $2.82 B | -67.61% |
| 2011-12-31 | $8.73 B | 19.61% |
| 2010-12-31 | $7.30 B | -14.25% |
| 2009-12-31 | $8.51 B | 3.01% |
| 2008-12-31 | $8.26 B | 271.46% |
| 2007-12-31 | $2.22 B | -44.56% |
| 2006-12-31 | $4.01 B | -30.8% |
| 2005-12-31 | $5.79 B | -22.41% |
| 2004-12-31 | $7.47 B | 36.96% |
| 2003-12-31 | $5.45 B | 36.8% |
| 2002-12-31 | $3.98 B | -29.45% |
| 2001-12-31 | $5.65 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $23.51 B | 161.47% | 🇺🇸 USA |
 Novartis NVS | $12.26 B | 36.30% | 🇨🇭 Switzerland |
 Pfizer PFE | $22.73 B | 152.72% | 🇺🇸 USA |
 AbbVie ABBV | $9.22 B | 2.60% | 🇺🇸 USA |
 Eli Lilly LLY | $3.66 B | -59.21% | 🇺🇸 USA |
 Amgen AMGN | $31.56 B | 250.87% | 🇺🇸 USA |
 Sanofi SNY | $14.35 B | 59.54% | 🇫🇷 France |
 Biogen BIIB | $5.04 B | -43.95% | 🇺🇸 USA |
 Merck MRK | $13.19 B | 46.66% | 🇺🇸 USA |
 AstraZeneca AZN | $6.46 B | -28.16% | 🇬🇧 UK |